| Target Price | $81.60 |
| Price | $80.29 |
| Potential |
1.63%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2026 .
The average Pieris Pharmaceuticals, Inc. target price is $81.60.
This is
1.63%
register free of charge
$126.00
56.93%
register free of charge
$50.49
37.12%
register free of charge
|
|
| A rating was issued by 19 analysts: 18 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2026 of
1.63%
register free of charge
|
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 02 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Oct 09 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 02 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Sep 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


